KAI Pharmaceuticals’ KAI-4169 will be the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in support of KAI’s upcoming clinical trials.


KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients. Formatech plans to complete the production run of KAI-4169 in the first quarter of 2010.

Previous articleHow Biotech Unions Could Save Companies and Revitalize Pipelines
Next articleScripps Research Institute to Use ISCO’s Parthenogenetic Stem Cells